Inclusion Criteria:

- All patients must have histologically confirmed invasive cancer of the head and neck.

- Irradiation to both neck sides is required.

- Standard radiation techniques would irradiate most of both parotid glands to a high
dose (>50 Gy). Patients with oropharyngeal, oral, nasopharyngeal, hypopharyngeal and
advanced laryngeal cancer are expected to fulfill this requirement.

- Patients with resectable disease that is either measurable, evaluable or
non-measurable disease (post-operative) will be eligible.

- Karnofsky performance status >60

- Patients receiving or not receiving chemotherapy are eligible.

- All patients must sign an informed consent.

- Pre-treatment laboratory criteria:

- WBC > 3500/ul, granulocyte > 1500/ul.

- Platelet count > 100,000/ul.

- Creatinine clearance > 60 cc/min. to receive cisplatin; creatinine clearance
30-59 cc/min to receive carboplatin.

- Bilirubin < 1.5 mg% with no evidence of obstructive liver disease.

- AST and ALT equal to or less than 2.5 x upper limit of normal.

Exclusion Criteria:

- Patients who received past irradiation to the head and neck are not eligible.

- Prior head and neck malignancy or history of other prior non-head and neck malignancy
within the past 3 years.

- Prior head and neck radiation or prior chemotherapy.

- Documented evidence of distant metastases.

- Active infection.

- Pregnancy or lactation; patients must use effective contraception during the course
of the clinical trial.

- Any medical or psychiatric illness which in the opinion of the principal investigator
would compromise the patients ability to tolerate this treatment.

- Patients residing in prison.

- Age < 18 years.